Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.72 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992122 | 0.85 | MITF (0.74) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL7905910 | 0.85 | MITF (0.74) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5992289 | 0.84 | ALDH1A1 (1.00) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12679652 | 0.84 | MITF (0.72) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL18569422 | 0.84 | KDM4E (0.72) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL11816128 | 0.83 | MITF (0.71) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL12679651 | 0.83 | MEN1 (0.70) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5993964 | 0.82 | ALDH1A1 (0.97) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5992200 | 0.82 | NPC1 (0.65) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL4604800 | 0.81 | ALDH1A1 (0.64) | MITFALDH1A1SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | claimed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | claimed |
| US-6995285-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050267215-A1 | ATP binding cassette transporter 1 (ABCA-1); increases high density lipoprotein (HDL) levels; use treating coronary artery disease; N-phenyl-N-(2-hydroxy-cyclohexyl)-2-(1,3,3-trimethyl-bicyclo[2.2.1]hept-2-ylamino)acetamide for example | CV THERAPEUTICS, INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2003103651-A1 | COMPOUNDS OF THE FORMU;A R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CAD OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267215-A1 | ATP binding cassette transporter 1 (ABCA-1); increases high density lipoprotein (HDL) levels; use treating coronary artery disease; N-phenyl-N-(2-hydroxy-cyclohexyl)-2-(1,3,3-trimethyl-bicyclo[2.2.1]hept-2-ylamino)acetamide for example | ABCD3, ABCF1, ABCC2 | MITF 1473/4885ALDH1A1 459/4885SMN1; SMN2 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.